Peptides: the class of drugs Big Pharma tried to bury
多肽：大药厂最想你别知道的一类药
Dr. Alex Tatum — urologist, men's health specialist — walks Steven Bartlett through every peptide on the biohacking table. Why the FDA banned nineteen working medicines overnight in 2023. What happens when seven of them become legal again in July 2026. And why Silicon Valley founders are already stacking them.
泌尿科医生、男性健康专家 Alex Tatum 把桌上每一瓶多肽都讲了个遍：FDA 为什么能在 2023 年一夜之间封禁 19 种真正有效的药？2026 年 7 月要解禁的那 7 种又意味着什么？硅谷创始人早已偷偷在打——他们到底在打什么。
🧩 What Is a Peptide, Exactly?
🧩 多肽到底是什么
The one-sentence answer: a peptide is a short chain of amino acids — a small snap-together piece of protein. The useful analogy is keys versus hammers.
一句话版本：多肽就是一小段氨基酸拼起来的链条——可以把它想成蛋白质的"小积木"。真正有用的类比是"钥匙 vs 锤子"。
Amino acids are the Lego bricks that proteins are built from. A peptide is a small snap-together piece — usually under fifty bricks long. Pick different bricks, snap them in a different order, and you've built a completely different tool: one that unlocks a specific cellular receptor and leaves the rest of the body alone.
氨基酸是蛋白质的"积木块"。多肽就是用这些积木拼出来的一小段结构，通常不到五十块。换一套积木、换一种拼法，就能造出一把完全不同的工具——精准对上某个细胞受体，对身体的其他部分完全不碰。
Most drugs you've ever taken are small molecules — chemical hammers. A hammer can do a lot of useful work, but it doesn't particularly care what it hits. That's why a large share of small-molecule drugs fail FDA trials with off-target side effects. Peptides are the opposite: they're keys, cut with enough precision to fit one lock and no others.
你吃过的大多数药都是小分子药——相当于化学锤子。锤子能干不少活，但它不挑目标。这就是为什么很多小分子药会卡在 FDA 试验里——打得到的东西太多，副作用也多。多肽正相反：它是钥匙，切得足够精准，只开一把锁。
The question isn't what peptides can do. It's what can't they do — and if they can't yet, can we design one that can?
现在的问题不是"多肽能做什么"——而是"它做不了什么"。就算暂时做不到的事，我们能不能设计一个新的多肽去做？
— Dr. Alex Tatum
— Alex Tatum 医生
The first peptide medication in human history was insulin, isolated in 1921. Fifty-six amino acids, two chains, nothing else in the pharmacy does what it does and as cleanly. In 1985, urology got its own breakthrough — leuprolide, a peptide that shut down testosterone production in prostate-cancer patients with surgical precision. Two proofs, separated by sixty-four years, that a molecule cut to fit could solve problems that blunt instruments couldn't.
人类历史上第一个多肽药是 1921 年分离出来的胰岛素——56 个氨基酸、两条链，药房里没有第二样东西能把这件事做得这么干净。1985 年，泌尿科等来了自己的突破：亮丙瑞林（leuprolide），一种精准关闭前列腺癌患者睾酮分泌的多肽。相隔 64 年的两次证明：精心设计的分子能解决钝器干不了的问题。
Fast-forward four decades. We now have the tools to design keys for almost any lock in the body. Which is how we ended up here, on a podcast table piled with vials.
再过四十年，我们已经能给身体里几乎每一把锁去配一把钥匙——于是才有了今天这张摆满小瓶子的播客桌。
⚖️ How We Got Here — The Regulatory Story
⚖️ 来龙去脉 · 监管这条暗线
In 2013 the Supreme Court accidentally killed Big Pharma's incentive to develop non-patentable drugs. Ten years later, the FDA banned nineteen working peptides overnight. Here's how.
2013 年最高法院一份判决，顺手掐断了大药厂开发"非专利分子"的动力。十年后，FDA 在一夜之间封禁了 19 种早已在用的多肽。故事是这样的。
In 2013 the Supreme Court decided AMP v. Myriad Genetics. The case was about breast-cancer genes, but the ruling had an accidental second effect: you can't patent something that exists naturally in the human body. If pharma can't own a molecule, there's no commercial incentive to spend a hundred million dollars bringing it through FDA trials. Peptides — which are often nature-identical or close to it — fell squarely into that dead zone.
2013 年，美国最高法院判决了 AMP v. Myriad Genetics 案。案子本身是关于乳腺癌基因的，但判决书有一条意外的"副作用"：自然存在于人体里的东西不能被申请专利。没有专利保护，大药厂就没理由花一亿美金去推一个分子过 FDA——而多肽，恰恰是那种"和天然分子非常像"的东西，一下掉进了这块没人理的空白区。
Around the same time, a compounding pharmacy in New England shipped contaminated steroid injections. The resulting fungal-meningitis outbreak killed 64 people. Congress asked the FDA to take over oversight of compounding pharmacies — small custom-formulation shops that had quietly been making non-patented peptides for physicians who wanted them.
差不多那几年，新英格兰有一家复方药房（compounding pharmacy）出了大事——一批被污染的类固醇注射剂导致 64 人死于真菌性脑膜炎。国会要 FDA 把这类复方药房的监管权一并接管。而复方药房，正是那些"小作坊式"的定制药房——许多医生想给病人开的非专利多肽，就是它们在悄悄做。
The three-bucket sorting
三类分级
The new rules sorted everything compounders made into three categories. Category 1 — allowed, on a defined list. Category 2 — banned, too dangerous. Category 3 — needs more data. The most promising peptides landed in Category 1. Doctors prescribed them. Patients did well.
新规把复方药房能做的所有化合物分成三类。第一类：允许，有明确清单。第二类：禁止，风险太高。第三类：数据不足，待定。当时最有潜力的那批多肽，统统被分进了第一类。医生照开，病人反馈良好。
For about nine years, it worked. Physicians like Tatum wrote prescriptions. Compounding pharmacies filled them. Then, in 2023, the FDA moved nineteen of those peptides from Category 1 to Category 2 — overnight. Compounding pharmacies emailed their partners: we can't make this anymore, we're sorry. The official reason was "insufficient safety data." Tatum's patients hadn't reported adverse events. The compounders hadn't reported adverse events. Nothing in the population warranted the reclassification.
这套体系跑了大约九年，顺畅运行。像 Tatum 这样的医生照开处方，复方药房照做。然后——2023 年——FDA 把其中 19 种多肽一夜之间从第一类划到第二类。复方药房给合作医生发邮件：这些我们不能再做了，抱歉。官方理由："安全性数据不足"。但 Tatum 的病人没有上报不良事件，复方药房也没有上报不良事件。换句话说，人群里找不出任何一件足以支撑这次改判的事。
Tatum's reading, shared by Robert F. Kennedy Jr. in public statements since: a thriving non-patentable market was money flowing past commercial pharma. A phone call to the right regulator is cheaper than a lawsuit.
Tatum 自己的解读（以及 RFK Jr. 后来公开说过的一个版本）是：一个无法被申请专利、却规模巨大的市场，意味着钱正在绕过大药厂。打一个电话给合适的监管官员，远比打一场官司便宜。
Two years pass. TikTok discovers peptides. The forbidden-fruit effect kicks in. Search volume for the word climbs four hundred percent. And on April 15, 2026 — the day this episode aired — the FDA announced it would reconsider seven of the banned peptides in July 2026 for a move back to Category 1.
两年过去。TikTok 发现了"多肽"这个词。禁果效应启动——这个词的搜索量飙升了四倍。然后，在 2026 年 4 月 15 日（也就是这期播客上线的当天），FDA 发公告：2026 年 7 月将重新评估其中 7 种多肽，准备把它们挪回第一类。
The truth isn't that these pharmaceutical companies are evil. The truth is maybe a little bit more ominous. They are large machines designed to prioritize profit over everything. And everything is everything.
事情的真相并不是说这些药厂"有多坏"——更让人不寒而栗的是：它们就是一台台设计出来只为追逐利润的大机器。而"一切"，就是字面上的一切。
— Dr. Alex Tatum
— Alex Tatum 医生
📒 The Peptide Directory
📒 多肽图鉴（逐一拆解）
The middle of the podcast is Tatum walking vial by vial through every peptide on his table — healing, metabolic, growth hormone, skin, sexual, cognitive, performance. Here's the full catalog, grouped by what they do and tagged with current US legal status.
播客中段，Tatum 一瓶一瓶把桌上所有多肽讲了一遍——修复的、代谢的、促生长激素的、美容的、性功能的、认知的、运动表现的。下面按用途分类，每一个都标注它在美国当下的法律状态。
Status legend — each card carries one of five tags:
状态说明——每张卡片都带有以下五种标签之一：
- Cat 1 · Commercial
- on the market today
- Up July 2026
- pending FDA review
- Cat 2 · Banned 2023
- currently illegal to compound
- Research-Use Only
- gray market
- Historical
- for context
- Cat 1 · 合法在售
- 现在就能买到
- 2026 年 7 月待审
- 等 FDA 裁决
- Cat 2 · 2023 被禁
- 目前不能复方合成
- 仅供研究
- 灰色市场
- 历史背景
- 仅作参考
🩹 Healing & Tissue Repair
🩹 修复与组织再生
Synthetic version of a peptide naturally found in the human gut. Enhances blood-vessel growth and tissue repair at injury sites. In rat studies, animals with fully transected Achilles tendons regrew and healed with nothing but BPC-157. So well-tolerated that researchers have never identified an LD1 — the dose that hurts even 1% of subjects. Also under investigation for ulcerative colitis.
一种在人体肠道里天然存在的多肽的合成版。能在受伤部位促进血管生长和组织修复。老鼠实验里，跟腱被彻底切断的大鼠仅靠 BPC-157 就能自发愈合。耐受性极高——研究者到现在都没找到它的 LD1（伤害到 1% 受试者的最低剂量）。溃疡性结肠炎的研究也在跟进。
The "brother" of BPC-157. Where BPC-157 stimulates blood-vessel growth, TB-500 improves blood flow into the injured area — sending the cells needed to rebuild the tissue matrix that was torn apart. Commonly stacked with BPC-157 for acute injury protocols.
BPC-157 的"兄弟"。BPC-157 负责长血管，TB-500 负责改善受伤区域的血流——把重建组织基质所需的细胞送到位。急性损伤协议里两者经常搭配使用。
A tripeptide (three amino acids) linked to angiogenesis and tissue repair, especially studied in inflammatory bowel contexts. The smallest compound in this group — elegant, targeted, low side-effect profile.
一种三肽（只有三个氨基酸），与血管生成和组织修复相关，在肠道炎症方向有较多研究。这组里结构最简单的一个——精巧、靶向、副作用谱小。
⚖️ Metabolic — The GLP-1 Wave
⚖️ 代谢类 · GLP-1 浪潮
The blockbuster that opened the class. A GLP-1 receptor agonist that slows gastric emptying — food absorbs more gradually, glucose spikes flatten, insulin response softens. Novo Nordisk.
打开这一整个品类的现象级药物。GLP-1 受体激动剂，通过减缓胃排空让食物吸收更平缓，血糖曲线更平，胰岛素负担更轻。诺和诺德出品。
Eli Lilly's answer. A dual agonist — it hits GLP-1 and GIP, a second gut-hormone receptor. Produces more weight loss per milligram than any approved product on the market. Tatum takes a small dose himself.
礼来的回击。双靶点激动剂——同时作用于 GLP-1 和第二个肠道激素受体 GIP。目前市面上所有获批药物里，单位毫克带来的减重幅度最高。Tatum 自己也在打小剂量。
The one Tatum calls "the Ferrari of GLP-1s." A triple agonist — GLP-1, GIP, and glucagon. The glucagon hit is the kicker: it tells your liver to mobilize stored fat for energy. So retatrutide doesn't just shed pounds — it produces the best liver-health improvements Tatum has ever seen (relevant for NASH patients). Phase 2 trials showed ~24% total body-weight loss at 48 weeks. Bodybuilders are already buying it research-use-only. Lilly will own the patent.
Tatum 口中"GLP-1 里的法拉利"。三靶点激动剂——GLP-1、GIP，加上胰高血糖素。第三个靶点是杀手锏：它让肝脏把储存的脂肪动员出来当燃料。所以它不只是减重——Tatum 说，他从业这些年见过最好的肝脏指标改善就出在这个药上（对 NASH 患者尤其有意义）。二期临床 48 周数据显示，体重下降约 24%。健美圈早已在灰色市场买来用。专利归礼来。
Not peptides — monoclonal antibodies, the "older brother" of peptides. Designed to preserve muscle in a caloric deficit by inhibiting myostatin, the protein that signals your body to break muscle down. If GLP-1s shrink you, these keep the muscle on while it happens. Bimagrumab is Lilly's (acquired from Versanis for $1.925B in 2023). The real second punch.
严格说不是多肽——是单克隆抗体，属于多肽的"大哥"类别。它们专门对付肌肉抑制素（myostatin）——这个蛋白负责告诉你的身体"拆肌肉吧"。GLP-1 把你瘦下来的同时，这类药负责保住你的肌肉。Bimagrumab 归礼来（2023 年从 Versanis 以 19.25 亿美元买下）。是接在 GLP-1 后面的第二记重拳。
💪 Growth Hormone Axis
💪 生长激素轴
A growth-hormone-releasing-hormone analog. Pushes the pituitary to pulse out more natural GH. Almost always paired with Ipamorelin for a synergistic effect.
生长激素释放激素（GHRH）的类似物。刺激垂体按脉冲方式多释放天然生长激素。几乎一定搭配 Ipamorelin 使用以发挥协同效应。
A ghrelin receptor agonist that triggers clean, pulsed GH release with minimal side effects. The second half of the most common biohacker GH stack (CJC-1295 + Ipamorelin).
ghrelin 受体激动剂，能以脉冲式方式释放生长激素，副作用极小。是最经典的"生长激素栈"(CJC-1295 + Ipamorelin) 里的另一半。
Earlier-generation growth-hormone-releasing peptides. Tissue repair, fat loss, muscle support. Mostly replaced in modern protocols by the CJC-1295 / Ipamorelin stack, but still widely discussed.
上一代生长激素释放肽，用于组织修复、减脂、辅助增肌。现代方案里已基本被 CJC-1295 + Ipamorelin 取代，但仍被广泛讨论。
One of the peptides that survived the ban. Originally FDA-approved for HIV-related lipodystrophy — boosts growth hormone, and happens to be uniquely good at stripping visceral belly fat. Bodybuilders use it for cutting.
2023 年那一波封禁里没被封的少数几个之一。最初因艾滋相关脂肪代谢异常获批，作用是提升生长激素水平——而且特别擅长剥除内脏脂肪。健美圈在赛前减脂期经常用。
Growth hormone itself, not a releasing peptide. The blunt instrument. Used correctly it improves sleep, body composition, recovery. Abused, it causes insulin resistance, numb hands from joint effusion, and — in bodybuilders who overdo it — permanent changes to facial bone structure (acromegaly).
生长激素本身，不是"促释放"的那种。最钝的武器。用对剂量能改善睡眠、体成分、恢复；滥用则会引起胰岛素抵抗、关节腔积液导致手指发麻；被长期大剂量滥用的健美者，面部骨骼会永久增粗（肢端肥大症）。
A longer-acting version of insulin-like growth factor 1 — the downstream messenger of growth hormone. The one peptide that actually nudges muscle mass on its own. Not anywhere near enough to replace lifting. "You still have to go to the gym."
胰岛素样生长因子 1 (IGF-1) 的长效版——生长激素下游的信号分子。是这张表里真正能自己给你增一点点肌肉的多肽。但"一点点"离替代举铁差得远。"你还是得去健身房。"
Technically a small molecule, not a peptide — but lumped into the 2023 ban because it works the same receptor (ghrelin). Orally available, which is rare in this class. Stimulates GH release and profound hunger — originally useful for cachexia patients on cancer treatment.
严格讲是小分子，不算多肽；但它作用在同一个受体（ghrelin），所以 2023 年一起被打包禁掉。口服有效，这在这一类里很罕见。能促生长激素释放，同时强烈刺激食欲——最初是给肿瘤恶病质的病人补身体用的。
✨ Skin, Hair & Sexual Function
✨ 皮肤、毛发与性功能
A copper-carrying tripeptide whose concentration in the body drops as you age. Applied topically, it's been shown to boost collagen and elastin — the same proteins expensive laser treatments are trying to rebuild. Topical GHK-Cu is openly sold as a cosmetic ingredient. Tatum uses it for rosacea with good results. Injectable GHK-Cu was swept up in the 2023 ban.
一种带铜离子的三肽，体内浓度随年龄下降。外用时已被证实能促进胶原蛋白和弹性蛋白合成——就是那些贵价激光项目想重建的东西。外用的 GHK-Cu 作为化妆品成分公开销售。Tatum 自己用它缓解玫瑰痤疮，效果不错。注射剂型在 2023 年那波一起被禁了。
A melanocortin receptor agonist. Two things happen when you inject it: deep tanning after minimal UV exposure, and — in Tatum's memorable phrasing — "the most impressive erections you've ever had." Safety concern: because it stimulates melanocytes, there's theoretical melanoma risk.
黑皮素受体激动剂。注射后会发生两件事：只需很少紫外线就能晒出深色古铜肤色；以及——用 Tatum 的原话——"你一辈子没见过的那种勃起"。安全顾虑：它会刺激黑素细胞，理论上可能增加黑色素瘤风险。
A Melanotan II derivative that kept the sexual-function effect but lost the tanning. FDA-approved (brand name Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Widely used off-label for erectile dysfunction in men.
Melanotan II 的衍生物——保留了性功能方面的效果，但去掉了晒黑。以 Vyleesi 的品牌名获得 FDA 批准，用于绝经前女性的性欲减退障碍 (HSDD)。男性的勃起功能障碍也常见超说明书使用。
🧠 Cognitive & Sleep
🧠 认知与睡眠
A seven-amino-acid peptide originally developed in the Soviet Union. Administered intranasally — absorbs through the mucous membrane straight into the brain. Post-TBI and post-stroke patients showed faster recovery in original Russian trials. Upregulates neural pathways involved in attention and sentence construction. Tatum's recommendation for cognitive work.
七肽，由苏联最先研发出来。鼻腔喷雾给药——通过鼻黏膜直接进入大脑。最初俄方的临床试验显示它能加速颅脑外伤和中风患者的恢复。它还能上调与注意力和语言组织相关的神经通路。Tatum 在节目里说：如果要靠脑子吃饭，这个是他会考虑的。
Another Russian-origin peptide. Anxiolytic — calms without sedating, lets sleep happen naturally. Promotes the deep delta-wave activity that makes sleep restorative rather than just long.
同样出自俄罗斯的一种多肽。抗焦虑——让人放松但不让人犯困，给睡眠"腾位置"。能促进深度 delta 脑波，让睡眠真正起到修复作用，而不是只"睡得久"。
Regulates the circadian rhythm. Biohackers use it for jet lag and shift-work recovery. Tatum: this is the one he'd take for travel — if he could.
调节昼夜节律。生物黑客圈用它对付时差和倒班后的生理节律紊乱。Tatum 自己的原话：如果哪天合法了，这是他出差时会带的。
A tetrapeptide that upregulates telomerase — the enzyme that repairs the protective cap on the end of every chromosome, which shortens each time your cells divide. Sold by some clinics as a "fountain of youth" compound. Tatum is skeptical of the longevity claims but sees real evidence for its role in pineal-gland regulation and sleep-wake cycles.
一种四肽，能上调端粒酶——专门修复染色体末端那段"保护帽"(端粒)的酶，而端粒每次细胞分裂就会短一截。一些诊所把它当作"青春之泉"来卖。Tatum 对抗衰的说法持保留态度，但他承认它在松果体调节和睡眠-觉醒周期上确有证据。
🏃 Performance & Hormones
🏃 运动表现与激素
A mitochondrial-derived peptide that upregulates the ATP energy pathway — your cellular gas tank. Improves VO₂ max and exercise tolerance. The biohacker community calls it "exercise in a vial," though Tatum is careful to note: the muscle gains still require actually exercising.
一种源自线粒体的多肽，能上调ATP 能量通路——也就是细胞的油箱。能提升 VO₂ max 和运动耐力。生物黑客圈管它叫"小瓶里的有氧"。Tatum 提醒：想要真正增肌，这瓶东西替代不了你去跑去举。
Famous for its role in labor and bonding. Also used in compounded doses within fertility and sexual-health protocols — one of the peptides that stayed legal through the 2023 reclassification.
以分娩和情感连结闻名。在复方处方里也用于生育和性健康方案的小剂量组合——是 2023 年那波没有被降级的少数几种之一。
🏛️ Historical & Context
🏛️ 历史与背景
The first peptide medication in human history. Fifty-six amino acids in two chains. Isolated by Banting, Best, Macleod, and Collip at the University of Toronto in 1921. Defined the category.
人类历史上第一个多肽药物。56 个氨基酸、两条链。1921 年由多伦多大学的 Banting、Best、Macleod、Collip 四人组分离出来。这一整个品类都是从它开始的。
FDA-approved 1985. A GnRH analog that shuts down testosterone production in prostate-cancer patients. Proof that a surgically precise peptide could do what blunt instruments couldn't — opened the door for the class that followed.
1985 年获 FDA 批准。GnRH 类似物，能关闭前列腺癌患者的睾酮分泌。它证明了"精准切割"的多肽能做到钝器做不到的事——替后面一整代多肽药物开了门。
Sitting on the table as a pointed cautionary example. "People take it and think it's going to make them live forever," Tatum says on tape. "Don't take this. It literally will stain your nails blue and your hair blue." Methylene blue has legitimate clinical uses — treating methemoglobinemia — but the fringe longevity micro-dosing trend isn't one of them.
这瓶摆在桌上，是 Tatum 特意拎出来的反面教材。原话："有人拿它当长生不老药吃——千万别。它会把你的指甲和头发真的染蓝。"亚甲蓝在临床上确有合法用途（治高铁血红蛋白血症），但长寿圈的"每日微剂量"潮流不在其中。
💉 How You Actually Take Them
💉 到底是怎么打进去的
Peptides are protein fragments, so your gut treats them like dinner. Which means almost everything in the directory above is injectable — and the politics of who controls the needle is the real fight right now.
多肽本质上是蛋白质的片段，所以你的胃会把它们当晚饭消化掉。换句话说，上面图鉴里的东西几乎都只能靠打针进体内——而"针头归谁管"，才是当下真正在打的那场仗。
If you swallow a peptide, your stomach breaks it apart into free amino acids — the same way it breaks down a piece of chicken. One narrow exception: a gut-stable form of BPC-157 engineered to survive stomach acid. For everything else, it's an injection.
你把多肽吞下去，胃会把它拆成一堆游离氨基酸——跟消化一块鸡肉没区别。唯一的例外是某种特殊设计过的 BPC-157，能抗胃酸活下来。除此之外，统统得靠打。
Most peptides go in subcutaneously — under the skin of the belly or thigh, with a tiny insulin-sized needle. "Pinch an inch, push," as Tatum tells patients. Commercial GLP-1 products like Mounjaro come in auto-injector pens that dose by click and fire themselves. Compounded peptides from a pharmacy come in vials; you draw them up into a syringe yourself. Both are within reach of a careful patient.
绝大多数多肽走皮下注射——肚皮或大腿，一根胰岛素级别的小针，"捏起一寸皮，推进去"。像 Mounjaro 这类商用 GLP-1 是自动注射笔，拨剂量、按一下就完事。复方药房做的多肽则是小瓶装，自己用注射器抽出来打。两种方式，只要认真做功课的病人都能自己上手。
The Lilly-vs-compounder flashpoint
礼来 vs 复方药房的真正战场
Compounded tirzepatide is the exact same molecule as Lilly's Mounjaro. The compounded version offers something the pen doesn't: the ability to micro-dose — split a weekly shot into three or four smaller ones to avoid the nausea many patients get from a full blast. This is legitimate customization; it's the whole point of compounding pharmacies existing. Lilly and Novo Nordisk have been lobbying the FDA hard to shut compounders down. The FDA commissioner has tweeted more about compounded GLP-1s, Tatum notes, than about diabetes and heart disease combined.
复方药房做的替尔泊肽，活性分子和礼来 Mounjaro 一模一样。但复方版有一样笔装给不了的东西——可以微剂量拆分：把一周一针拆成三针或四针的小剂量，避免很多病人一针下去就恶心反胃的那种反应。这本来就是复方药房存在的意义：个性化。礼来和诺和诺德正在对 FDA 使劲游说，要把复方药房关掉。Tatum 指出，FDA 专员发关于"复方 GLP-1"的推文，比他发糖尿病和心脏病的加在一起还要多。
⚠️ No Free Lunch
⚠️ 没有免费午餐
Everything is a trade-off. The question to ask of any tool offering dramatic upside is: what's the cost.
任何东西都有代价。任何工具只要上行收益惊人，必须马上问一句：下行成本在哪。
Research-use-only peptides sit in a regulatory loophole — labeled "not for human consumption" to dodge FDA jurisdiction. What you receive in the vial may or may not be the molecule on the label. It may or may not be free of endotoxins. Tatum's analogy: gas-station sushi. Sometimes fine, sometimes very much not.
"仅供研究"的灰色多肽钻的是监管漏洞——标签上写着"不供人用"，法律上就躲开了 FDA。至于瓶子里装的究竟是不是标签上写的分子、有没有内毒素污染——说不准。Tatum 的类比是"加油站寿司"：有时候没事，有时候非常有事。
When GLP-1s put you in a steep caloric deficit, your body burns fat — and muscle. Muscle is the most metabolically active tissue you have; losing it during a shrink cycle undermines the very insulin sensitivity the drug was supposed to improve. Currently the only reliable muscle-preservation tool on top of GLP-1s is testosterone — which isn't an option for men trying to conceive, or most women. Myostatin-inhibitor biologics coming behind this wave are the real fix, but they're still years out and will be patented.
GLP-1 把你拉进深度热量赤字，身体开始烧脂肪——也同时烧肌肉。肌肉是体内最活跃的代谢组织，减重期掉肌肉，反过来会削弱这个药本应改善的那件事（胰岛素敏感性）。目前唯一靠谱的"减脂保肌"配方是在 GLP-1 基础上叠加睾酮——可想生孩子的男性不能用，大多数女性也不合适。接在这一波后面的肌抑素抑制剂（生物药）才是真正的解法，但它还有好几年才上市，而且一定有专利。
Growth-hormone-axis peptides, pushed too hard, cause glucose dysregulation, numb hands from joint effusion, and — in long-term abuse — acromegaly. Melanotan II carries theoretical melanoma risk. Somatropin at high doses permanently changes facial bone structure. No compound in the directory above is free.
生长激素轴的多肽一旦剂量过头，会出现血糖失调、关节腔积液导致手指发麻；长期滥用还会引起肢端肥大症。Melanotan II 存在理论上的黑色素瘤风险。somatropin 高剂量会永久性改变面部骨骼。图鉴里没有一样是完全"免费"的。
Every pathway-modifying drug stops modifying the pathway the moment you stop taking it. GLP-1 data is blunt: stop the shot, keep the same life, the weight returns. What preserves the result is lifestyle change. Peptides buy you a runway — they don't replace the work. Staying on at a much lower maintenance dose is increasingly a strategy.
所有作用于某条通路的药，停药的那一刻就停止作用。GLP-1 的数据很直白：针停、生活不变，体重回来。真正守住减重成果的是生活方式本身。多肽只是给你争取一段助跑——不能替你跑。越来越多的方案是"低剂量长期维持"，而不是打一段停一段。
🌍 The Bigger Picture
🌍 更大的背景
US obesity rates, fertility trajectories, and the Enhanced Games in Las Vegas. Why peptides are a systemic answer to a systemic problem.
美国的肥胖率、男性生育力的下滑曲线、拉斯维加斯的"增强奥运"。为什么这批多肽是在回答一个"系统级"问题。
US obesity rates run between 40 and 70 percent depending on which BMI cutoff you use. Neither number is compatible with a healthy country. "Eat your greens and go to the gym" — Tatum loves that advice; it just isn't working at scale.
美国成年人肥胖率的数字在 40% 到 70% 之间摇摆——取决于你用哪一条 BMI 线来切。无论哪个数字，都说明这个国家离"健康"差得很远。"多吃菜、多进健身房"——Tatum 自己第一个喜欢这句话，但它在人群尺度上已经不够用了。
The second-order consequences are everywhere once you look for them. In the operating room, Tatum sees obese patients whose connective tissue is paper-thin — calorie-rich, protein-starved — so the fascia that literally holds them together gives way under a scalpel. In his fertility clinic, young men walk in with sperm counts so low he can't help them get pregnant until he helps them lose weight first. One patient last week increased his sperm count tenfold after losing 100 pounds on tirzepatide.
只要你去看，这件事的连锁反应到处都是。手术台上，Tatum 见过肥胖患者的结缔组织薄得像纸——热量过剩、蛋白质极度缺乏——连把人"扎起来"的筋膜都薄到一划就开。他的生育诊所里，年轻男性的精子数低到还没法帮他们造人，得先帮他们减下来。上周就有这么一位病人：用替尔泊肽掉了 100 磅体重之后，精子数翻了十倍。
The three fertility vials Tatum props up on the podcast — 1973 opaque, 2026 pale, 2045 clear — are a prediction, not a data point. If the last fifty years' trajectory continues, we land at clear water by 2045. The leading culprits: environmental toxins (microplastics, endocrine disruptors) and the much bigger modifiable one — metabolic disease.
那三个生育瓶——1973 的混浊、2026 的淡色、2045 的清水——不是一个已发生的数据点，而是一条外推。如果过去五十年的趋势不变，到 2045 年就是清水。元凶是环境毒物（微塑料、内分泌干扰物），以及那个大得多、而且可以改的因素——代谢疾病。
This isn't just for the biohackers. If we can eliminate metabolic dysfunction as a society, or even minimize it, maybe I'd finally work myself out of a job.
这不是给生物黑客们玩的。如果我们真能把代谢紊乱这个病在整个社会层面消灭掉——或者至少压到最小——说不定有一天，我这个职业就用不着我了。
— Dr. Alex Tatum
— Alex Tatum 医生
The Enhanced Games, May 21–24 in Las Vegas, are a side-show but a revealing one. An Olympics where performance-enhancing medication is permitted under medical supervision. $250,000 for first place. A million dollars for a world record. The underlying argument is the same one Tatum makes about peptides: the current regime drives the behavior it pretends to prevent — underground, unsupervised, contaminated. Better to do it in the light, with a doctor in the room.
5 月 21 到 24 号在拉斯维加斯办的"增强奥运 (Enhanced Games)"是个副本，但很说明问题：一场允许在医生监督下使用增强药物的奥运会。冠军 25 万美元，打破世界纪录的话 100 万美元。它背后的逻辑跟 Tatum 说多肽时的逻辑是同一个——你现在这套规则只会把它真正驱赶的行为赶到地下去：无人监管、质量无底。不如把它摆到桌面上，旁边站一个医生。
🪙 Silicon Valley's Obsession
🪙 硅谷的"神药"
Peptides have become, as one framing has it, "Silicon Valley's miracle drug." The revenue numbers are at parity with the entire consumer-AI industry.
有人把多肽叫作"硅谷的神药"——不是空话。它这一个品类的年收入已经可以和整个消费级 AI 行业打平了。
The combined 2026 revenue of semaglutide and tirzepatide alone is projected at over $55 billion. The combined revenue of the top four large-language-model companies is $58–62 billion. Before you even count compounded versions, research-use-only markets, or the peptides about to be legalized, a single drug class is at parity with all of consumer AI.
仅把 Semaglutide 和 Tirzepatide 两个药加起来，2026 年预期收入就超过 550 亿美元。全球排名前四的大语言模型公司加在一起，收入是 580 亿到 620 亿美元。也就是说——在你还没把复方版、灰色市场、以及即将解禁的那批多肽算进去之前，一个药物品类的规模已经和整个消费级 AI 持平了。
Why founders in particular? Anabolic steroids come with non-trivial health costs. Peptides offer a lot of the same levers — fat loss, recovery, cognition, sleep — with less collateral damage, and they fit naturally into an optimize-everything, DIY founder culture. Tatum has seen peptide stacks from Silicon Valley founders that, in his words, "blow my mind, and I'm a doctor."
为什么偏偏是创始人群体？合成代谢类固醇的代价不小。多肽给的是类似的操作杆——减脂、恢复、认知、睡眠——但副作用小得多，而且跟硅谷那种"什么都能优化、什么都能 DIY"的文化天然对口。Tatum 说他见过硅谷创始人的多肽搭配："我是医生，我都觉得那也太卷了。"
🕯️ The Human Thread — Why Dr. Tatum Fights for This
🕯️ 医生的另一面 · 他为什么为这件事拼
Before the podcast, the clinic, and the thousand prescriptions — a 3 a.m. hallway covered in blood, and an IVF room. The reason Tatum cares this much.
在他当上节目嘉宾、开上诊所、写下成千上万张处方之前——是一条凌晨三点的走廊，和一间 IVF 手术室。他在乎这件事，真正的理由是这个。
Before Tatum was a men's health specialist writing prescriptions and a founder running clinics, he was a surgical resident. Five years. Eighty- to one-hundred-hour weeks. The training that is — by design — engineered to break you, so that you can hold together in an operating room when it counts. It did break him. His own testosterone cratered. A photo of Tatum five years ago looks like a different person.
在成为今天这个开诊所、上节目、写处方的男性健康专家之前，Tatum 是外科住院医。五年，每周 80 到 100 小时。这种训练是被"设计来"击垮你的——因为医院希望你在真正的手术台上，无论怎么被击打都能稳住。它把他也击垮了。他自己的睾酮水平崩了。五年前的照片看上去是另一个人。
The inflection point: a kidney surgery on an uninsured patient at a county hospital. A complex tumor in a treacherous location; the patient's other kidney already failing. They swung for the fences. That night, postoperative bleed. Tatum and his attending went back in at 3 a.m. and evacuated blood until they found the source. They had to take the kidney. Tatum walked out of that operating room covered in it, sat down alone in a hallway, and cried — wondering whether any of this was worth doing.
转折点是一台肾脏手术。患者没有医保，住的是郡立医院，肾的位置极险，而且只剩这一个。他们拼了一把，做了一台相当高难度的手术。当天夜里——术后大出血。Tatum 和他的主治凌晨三点重新开腹，把血一直抽出来，直到找到出血点。最终还是把那颗肾摘了。Tatum 满身是血从手术室走出来，一个人坐在走廊里哭——那一刻他在想：这一切，到底值不值得。
The patient recovered. Tatum stayed with him through the rest of the hospital stay — literally held his hand. And afterward, something shifted. Tatum got checked out himself. Was diagnosed with low T. Started training differently. Rebuilt. The photo from five years ago is where he came from.
那位病人最终活了下来。之后 Tatum 就陪着他走完了剩下的住院日——是那种"真的拉着他的手"的陪着。从那之后，他自己的东西也开始转向：他去做了体检，被诊断出低睾酮，重新规划训练方式，一点点把自己修回来。五年前那张照片，就是他出发的地方。
He and his wife couldn't get pregnant when they first tried. They did IVF. He sat in that room, he says, "feeling like I wasn't a man" — because he was the one holding her hand and he didn't have an answer. Which is why, when he sees a young man in his clinic now who can't get his wife pregnant, or a middle-aged man whose hormones have flatlined, or a grandfather recovering from prostate-cancer treatment, it is not an abstraction. It's his father. It's his uncle. It's him.
他和太太第一次想要孩子的时候怀不上。最后做了 IVF。他坐在那间手术室里，用他自己的话——"感觉自己不算一个男人"——因为是他握着太太的手，但他给不出答案。所以今天诊所里来的每一个年轻丈夫、每一个激素崩盘的中年男人、每一位做完前列腺癌手术来求助的爷爷——对他来说都不是抽象的病人。是他父亲。是他叔叔。是他自己。
This is who I've been called to care for. I want my patients to have every tool physically possible to live their best quality of life — so they can be whole, so they can be happy, so they can be the best version of themselves for the people they love.
这就是我被召唤来照顾的人。我想让我的病人拿到每一件可能的工具，去过上他们能过的最好生活——这样他们才是完整的，才是开心的，才能在爱他们的人面前做最好的自己。
— Dr. Alex Tatum
— Alex Tatum 医生
That's the answer, when the question is why fight the FDA over seven peptides.
这就是答案——当问题是"一个人为什么会为七种多肽跟 FDA 死磕到底"的时候。
🔚 The Closer
🔚 收尾
The FDA meets in July. Seven peptides go on the table. Whatever the outcome, the class is here — the wave is larger than the regulation. The question is whether the framework catches up with the biology, or whether people who want access continue to find these tools through gray-market compounders with research-use-only labels and no quality control.
FDA 七月开会。七种多肽上桌。结果怎么样都好——这个品类已经到了，浪头比监管大得多。真正的问题是：监管框架会追上生物学，还是想用的人继续只能在贴着"仅供研究"标签、毫无质控的灰色渠道里找这些工具？
This is a Spark, not medical advice. Talk to your doctor. Ask better questions than "which peptide should I take" — ask what's the problem I'm trying to solve, and is a peptide the right tool for it?
这是一份科普 Spark，不是医疗建议。请找你的医生聊。别问"我该吃哪个多肽"——问的问题应该是：我要解决的是哪个具体问题？多肽真的是对的工具吗？